​

Rhythm Pharmaceuticals (RYTM) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Rhythm Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$189.76M

Latest Revenue (Q)

$51.30M

Main Segment (Y)

Product

Main Geography (Y)

Non-US

Rhythm Pharmaceuticals Revenue by Period

Rhythm Pharmaceuticals Revenue by Year

DateRevenueChange
2025-12-31$189.76M45.83%
2024-12-31$130.13M68.06%
2023-12-31$77.43M227.56%
2022-12-31$23.64M649.46%
2021-12-31$3.15M100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31-100.00%
2012-12-31--

Rhythm Pharmaceuticals generated $189.76M in revenue during NA 2025, up 45.83% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Rhythm Pharmaceuticals Revenue by Quarter

DateRevenueChange
2025-09-30$51.30M5.76%
2025-06-30$48.50M48.31%
2025-03-31$32.70M-21.82%
2024-12-31$41.83M25.80%
2024-09-30$33.25M14.35%
2024-06-30$29.08M11.98%
2024-03-31$25.97M7.15%
2023-12-31$24.23M7.69%
2023-09-30$22.50M17.08%
2023-06-30$19.22M67.59%
2023-03-31$11.47M30.48%
2022-12-31$8.79M105.18%
2022-09-30$4.28M-52.75%
2022-06-30$9.07M505.21%
2022-03-31$1.50M-17.56%
2021-12-31$1.82M76.75%
2021-09-30$1.03M275.18%
2021-06-30$274.00K682.86%
2021-03-31$35.00K100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30--

Rhythm Pharmaceuticals generated $51.30M in revenue during Q3 2025, up 5.76% compared to the previous quarter, and up 176.42% compared to the same period a year ago.

Rhythm Pharmaceuticals Revenue Breakdown

Rhythm Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24Dec 23Dec 22
License$-5.01M---
Product$194.77M$130.13M$77.43M-
License revenue---$6.75M
Product revenue---$16.88M

Rhythm Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (102.64%), and License (-2.64%).

Quarterly Revenue by Product

Product/ServiceDec 25Sep 25Jun 25Mar 25Dec 24Mar 24Jun 23Dec 22Sep 22Jun 22
License$10.03M$-5.01M$-5.01M$-5.01M------
Product$57.25M$51.30M$48.50M$37.72M$104.16M$25.97M----
Product revenue------$19.22M$8.79M$4.28M$2.31M
License revenue---------$6.75M

Rhythm Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Product (85.10%), and License (14.90%).

Rhythm Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 25Dec 24Dec 23
Non-US$61.22M$34.02M-
UNITED STATES-$96.11M$62.42M
Other Countries--$8.93M
GERMANY--$6.08M

Rhythm Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 25: Non-US (100.00%).

Quarterly Revenue by Country

CountryDec 25Sep 25Jun 25Mar 25Dec 24Sep 24
Non-US$18.27M$13.08M$16.52M$13.35M--
UNITED STATES----$72.81M$23.30M
Other Countries-----$6.33M
GERMANY-----$3.62M

Rhythm Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Dec 25: Non-US (100.00%).

Rhythm Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
KNSAKiniksa Pharmaceuticals$677.56M$180.85M
ARVNArvinas$262.60M$41.90M
RYTMRhythm Pharmaceuticals$189.76M$51.30M
SNDXSyndax Pharmaceuticals$172.35M$45.87M
VRDNViridian Therapeutics$70.85M$70.57M
STOKStoke Therapeutics$36.55M$10.63M
MGTXMeiraGTx$33.28M$3.69M
RNAAvidity Biosciences$18.75M$12.47M
QUREuniQure$16.10M$3.70M
RLAYRelay Therapeutics$15.36M-
CGEMCullinan Therapeutics--
AKROAkero Therapeutics--
SLDBSolid Biosciences--
BDTXBlack Diamond Therapeutics--
PTGXProtagonist Therapeutics--
VTYXVentyx Biosciences--
NUVLNuvalent--
RCKTRocket Pharmaceuticals--
RVMDRevolution Medicines--
ACLXArcellx-$7.55M
PLRXPliant Therapeutics--

RYTM Revenue FAQ

What is Rhythm Pharmaceuticals’s yearly revenue?

Rhythm Pharmaceuticals's yearly revenue for 2025 was $189.76M, representing an increase of 45.83% compared to 2024. The company's yearly revenue for 2024 was $130.13M, representing an increase of 68.06% compared to 2023. RYTM's yearly revenue for 2023 was $77.43M, representing an increase of 227.56% compared to 2022.

What is Rhythm Pharmaceuticals’s quarterly revenue?

Rhythm Pharmaceuticals's quarterly revenue for Q3 2025 was $51.3M, a 5.76% increase from the previous quarter (Q2 2025), and a 54.28% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $48.5M, a 48.31% increase from the previous quarter (Q1 2025), and a 66.80% increase year-over-year (Q2 2024). RYTM's quarterly revenue for Q1 2025 was $32.7M, a -21.82% decrease from the previous quarter (Q4 2024), and a 25.94% increase year-over-year (Q1 2024).

What is Rhythm Pharmaceuticals’s revenue growth rate?

Rhythm Pharmaceuticals's revenue growth rate for the last 3 years (2023-2025) was 145.08%, and for the last 5 years (2021-2025) was 5916.39%.

What are Rhythm Pharmaceuticals’s revenue streams?

Rhythm Pharmaceuticals's revenue streams in c 25 are License, and Product. License generated $-5.014M in revenue, accounting -2.64% of the company's total revenue Product generated $194.77M in revenue, accounting 102.64% of the company's total revenue, up 49.68% year-over-year.

What is Rhythm Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Rhythm Pharmaceuticals was Product. This segment made a revenue of $194.77M, representing 102.64% of the company's total revenue.